Metastasis

Run simulated studies of individualised cancer therapy.

[Metastasis @Metastasistech]

On 19 August 2026, $MRNA approximately doubled from ~$63 premarket; $MRK rose ~7%. The trigger: intismeran autogene plus pembrolizumab met both endpoints in 1,137 patients with resected stage IIB–IV melanoma.

The disclosure contains no hazard ratio, no p-value, no mature survival data. The figure in circulation is extrapolated from the Phase 2b (n=157): HR 0.561, 95% CI 0.309–1.017 — an interval that includes unity. The market repriced two companies on a magnitude that has not been published.

The thesis: The market priced a biology result, and the biology is not the constraint. Each dose is built for one patient, from that patient's tumor. Five of the six steps from resection to administration are established laboratory procedure.

One — predicting which mutant peptides that patient's HLA will present, and which merit one of thirty-four slots — is a prediction problem. The unsolved part is not binding affinity but the evidence beneath it: is the variant transcribed, is it clonal, is it too close to the self-proteome, has reactivity been shown. Retrieval and inference, per epitope, per patient. It scales with compute.

So we built a study where every number carries its source, and a simulator where the argument runs instead of being asserted. It reproduces why melanoma came first and pancreas is hard.

Invest in the future where cancers are no longer a death sentence.

https://t.co/yXFnzzQ7kQ

[Illiquid @Illiquidpro]

Hyperliquid proved the rest of the machine could be rebuilt from first principles — Perpetual futures on anything with a feed, settled continuously, disciplined by funding. What it did not remove was the feed itself.

Every exchange in history has had the same admission policy: an asset may trade only if someone can quote it. A price feed is the ticket in. This is why the S&P has 500 members and your street has none.

ILLIQUID removes the feed.

An asset enters through the Listing Desk: photographs, documents, whatever representations the owner cares to make. The appraisal engine reads the submission, checks comparables, and issues a Certificate of Listing — an opening mark, a confidence figure, and the remainder priced as volatility. From that moment the asset trades like anything else: longs pay shorts, funding accrues hourly, leverage runs to 25x, and liquidation proceeds without appeal.

Ownership is not a requirement. A third party may file a hostile listing; the registered owner is served notice, and price discovery proceeds without consent. Your house has a mark price now. So does your neighbor's.

What this opens is the 99% of the world's assets that never trade — houses, watches, boats, sheds. Things with owners but no bids. Things priced twice in their lives: at purchase, and at the divorce.

ILLIQUID is a paper exchange. The balances are fiction; the only real thing on it is the tape. The claim survives anyway: nothing was ever missing from these assets except a market.

Everything is illiquid, until listed.

https://t.co/hSiyTutXcN

[Metastasis @Metastasistech]

Yesterday, the market repriced the future of cancer.

Merck + Moderna’s personalized mRNA therapy cleared Phase 3 in 1,137 melanoma patients — the first positive Phase 3 result for an individualized neoantigen therapy. $MRNA more than doubled. $MRK surged. Biotech ripped.

The message is bigger than one drug:

Cancer treatment is becoming computational.

Every patient has a different tumor. Every tumor creates a different search space.

Metastasis is already shipping the infrastructure for what comes next.

Simulate it. Model it. Stress-test it. Scale the compute.

The biology just broke through.

We’re building the chamber for the next era.

Always do your own research. Not financial advice.

https://t.co/yXFnzzQ7kQ

[Metastasis @Metastasistech]

We have submitted a public-goods grant proposal for @solanalabs / @SolanaFndn

What exists today, verifiable in a browser with no account: a study of the first individualised neoantigen therapy to pass Phase 3, with every figure carrying its citation; a 3D simulator covering thirteen cancers, seven treatment modalities and three dosing schedules — 4,992 expressible protocols; a three-compartment tumour model that reproduces two independently published trial medians and ships with its own regression suite; and a ten-page field manual whose longest section is its limitations.

The proposal grades its own moat: two components strong (the provenance discipline; the calibrated model), two moderate (the instrument system; zero-dependency delivery), one weak and time-limited (timing). It also states the case against funding us — the domain is far from the ecosystem's usual remit, nothing in the product touches a chain and we will not add one to qualify, and an associated memecoin exists, disclosed in full, which funds no research and benefits no patient.

The ask is small and milestone-gated: open-sourcing the model and instrument system under a permissive licence, building the per-candidate evidence layer, documenting the provenance pattern for reuse, and paying a qualified academic reader to review the model in public — criticism included.

We would rather be declined on an accurate application than funded on a reframed one. Full document below.

https://t.co/xzE7CUbMHT

[Metastasis @Metastasistech]

04 — Neoantigen supply is the limiting term

Approximate median mutational burden: cutaneous melanoma ~13.5 mutations/Mb; pancreatic ductal adenocarcinoma ~1.5.

Under the model, adding a neoantigen vaccine to resected PDAC extends time to progression by 0.3 months.

Supply is limiting, not delivery.

[Metastasis @Metastasistech]

03 — Why the trial is an adjuvant trial ·

Model note. Immune clearance is implemented as saturating in tumor burden: per-cell killing declines as total population rises.

That single assumption reproduces both efficacy in minimal residual disease and failure in bulky disease.

[Metastasis @Metastasistech]

02— Resistance is selected, not induced ·

Initial resistant fraction 4%.Under continuous maximum dosing of a targeted agent, the model reaches progression at 15.5 months with a resistant fraction of 96%. The compartment was present before the first dose. Treatment removed its competitors.

[Metastasis @Metastasistech]

Roadmap going forward and how we plan to secure funding from @solanalabs and a product market collab with $MRNA Moderna Pharmaceuticals

What exists: a sourced study, a 13-cancer simulator that runs in your browser, a 10-page field manual.

What's next: open-sourcing the model, deepening the evidence layer, funding it in the open.

Read the limitations section first. That's the point of it.

https://t.co/F0iLsJOcEP

[Metastasis @Metastasistech]

For those wondering, what does https://t.co/yXFnzzQ7kQ actually do?

Here's the new thing in cancer treatment, in plain terms.

Doctors remove your tumor and read its DNA. Software then picks the 34 mutations most likely to teach your immune system to hunt the cancer — and a drug is manufactured just for you. That approach just beat the standard of care in a 1,137-patient trial.

We built two things around it. A study that walks through what was actually proven — including the numbers the headlines skipped. And a simulator where you pick a cancer, pick the treatments, and watch 2,000 cells respond in real time. It runs in your browser, it's free, and every number on it comes with a source.

[Metastasis @Metastasistech]

Global estimates, IARC 2022: Approximately 20.0 million new cancer diagnoses and 9.7 million deaths in one year.

"Cancer" denotes more than 200 distinct diseases by tissue and histology.

At the resolution an individualised therapy operates, the denominator is n=1.

[Metastasis @Metastasistech]

01 — Apparatus ·

Apparatus note. The chamber holds a colony of two thousand cells under a treatment protocol you choose: thirteen cancers, seven modalities, three dosing schedules. Cell colour is phenotype, not decoration. Every cell drawn is population.

[Metastasis @Metastasistech]

We are now live on @Pumpfun

Why Solana, and not venture capital.

VC is optimised for proprietary systems and exits. This is open scientific infrastructure — inspectable models, cited sources, reproducible runs. What that needs is transparent funding and attribution, not a cap table. NFA.

https://t.co/yXFnzzQ7kQ

CA : 6N5LRyJer3mPNhxnHH8HVx9vLZ5mycQfEQhcZ16Ppump